Moonlake Immunotherapeutics (MLTX)

$16.74 +0.40 (2.45%)
Market Cap 1.39B
Revenue (ttm) 0.00
Net Income (ttm) -227.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.23
Volume 1,439,720
Avg Vol 1,321,846
Day's Range N/A - N/A
Shares Out 85.11M
Stochastic %K 15%
Beta 1.06
Analysts Strong Sell
Price Target $33.38

Company Profile

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerla...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 415108022
Address:
Dorfstrasse 29, Zug, Switzerland
cranberry1
cranberry1 Aug. 19 at 7:54 PM
$MLTX 64
0 · Reply
badprecog
badprecog Aug. 19 at 7:45 PM
$MLTX Today is a very strong bio day, however I think once it is done going down, it will get back to $20 pretty quickly. At least that was my theory when I was trying to catch a falling knife yesteday.
1 · Reply
Mlbfan44
Mlbfan44 Aug. 19 at 7:44 PM
$MLTX
0 · Reply
pizzza
pizzza Aug. 19 at 7:28 PM
$MLTX
0 · Reply
Jkm11
Jkm11 Aug. 19 at 6:05 PM
$MLTX maybe someone knows something about something? Lol. Just some dumb humor to pass the time.
4 · Reply
Jkm11
Jkm11 Aug. 19 at 5:46 PM
$MLTX any explanation fot the out of the blue green candle? Weird after none in last week.
2 · Reply
perplex
perplex Aug. 19 at 5:08 PM
$MLTX That was quite a big volume candle for this time in the day..
2 · Reply
Horseblushew
Horseblushew Aug. 19 at 4:52 PM
$MLTX well now that you know i was 100% correct when i said this was a dead stock, do me a favor and tell that fucking scumbag pumper greasy, to go screw himself. this will be under $10 before you know it. BTW, did they get that break through drug designation greasy guaranteed??🤣🤣😂😂
0 · Reply
Antocar
Antocar Aug. 19 at 4:30 PM
$MLTX There remains uncertainty about SLK's efficacy in PsA. It is effective but has not yet proven to be a BIC. Therefore, the market is currently focusing on HS. Advanced results on PsA will be available in 2027, and then we'll see. At the moment, however, the euphoria surrounding SLK has greatly diminished.
0 · Reply
aletz
aletz Aug. 19 at 4:02 PM
$MLTX disappointing day, most bios are green and MLTX is not really budging, there's really very little excitement left and the management is doing a very poor job in marketing and promoting the science. They have hundreds of millions of dollars but has the most lame and boring linkedin posts.
1 · Reply
Latest News on MLTX
MoonLake price target raised to $50 from $45 at H.C. Wainwright

2026-08-17T08:23:56.000Z - 2 days ago

MoonLake price target raised to $50 from $45 at H.C. Wainwright

MoonLake's psoriatic arthritis drug meets key goals in late-stage trial

Aug 10, 2026, 8:07 AM EDT - 9 days ago

MoonLake's psoriatic arthritis drug meets key goals in late-stage trial

MoonLake Immunotherapeutics reports Q2 EPS (84c), consensus (90c)

2026-08-10T11:45:28.000Z - 9 days ago

MoonLake Immunotherapeutics reports Q2 EPS (84c), consensus (90c)

MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16

2026-08-10T11:40:14.000Z - 9 days ago

MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

Aug 10, 2026, 7:00 AM EDT - 9 days ago

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

MoonLake Immunotherapeutics Earnings release: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 9 days ago

MoonLake Immunotherapeutics Earnings release: Q2 2026

MoonLake Immunotherapeutics Quarterly report: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 9 days ago

MoonLake Immunotherapeutics Quarterly report: Q2 2026

MoonLake Immunotherapeutics 9M share Secondary priced at $20.00

2026-06-24T10:25:15.000Z - 2 months ago

MoonLake Immunotherapeutics 9M share Secondary priced at $20.00

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

Jun 23, 2026, 11:08 PM EDT - 2 months ago

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares

2026-06-22T20:17:49.000Z - 2 months ago

MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares

MoonLake Immunotherapeutics Announces Proposed Public Offering

Jun 22, 2026, 4:01 PM EDT - 2 months ago

MoonLake Immunotherapeutics Announces Proposed Public Offering

MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street

2026-06-22T17:45:23.000Z - 2 months ago

MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street

MoonLake Immunotherapeutics Transcript: Investor Day 2026

Jun 22, 2026, 8:00 AM EDT - 2 months ago

MoonLake Immunotherapeutics Transcript: Investor Day 2026

MoonLake Immunotherapeutics Slides: FY 2026

Jun 22, 2026, 8:00 AM EDT - 2 months ago

MoonLake Immunotherapeutics Slides: FY 2026

MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials

2026-06-22T01:20:59.000Z - 2 months ago

MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

Jun 21, 2026, 5:00 PM EDT - 2 months ago

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MoonLake Immunotherapeutics Earnings release: Q1 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

MoonLake Immunotherapeutics Earnings release: Q1 2026

MoonLake Immunotherapeutics Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

MoonLake Immunotherapeutics Quarterly report: Q1 2026

MoonLake price target raised to $45 from $40 at H.C. Wainwright

2026-05-11T10:50:53.000Z - 3 months ago

MoonLake price target raised to $45 from $40 at H.C. Wainwright

MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street

2026-05-10T19:10:05.000Z - 3 months ago

MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street

MoonLake says aligned with FDA on submission plans for sonelokimab

2026-05-10T18:50:45.000Z - 3 months ago

MoonLake says aligned with FDA on submission plans for sonelokimab

MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year

2026-05-10T18:50:05.000Z - 3 months ago

MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

May 10, 2026, 9:00 AM EDT - 3 months ago

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

MoonLake Immunotherapeutics Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

MoonLake Immunotherapeutics Proxy statement: Proxy filing

MoonLake Immunotherapeutics Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

MoonLake Immunotherapeutics Proxy statement: Proxy filing

MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial

2026-03-29T14:35:05.000Z - 5 months ago

MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Mar 28, 2026, 3:00 PM EDT - 5 months ago

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

MoonLake Immunotherapeutics management to meet with BTIG

2026-03-26T17:25:33.000Z - 5 months ago

MoonLake Immunotherapeutics management to meet with BTIG

MoonLake upgraded to Outperform from Underperform at Wolfe Research

2026-03-23T09:45:29.000Z - 5 months ago

MoonLake upgraded to Outperform from Underperform at Wolfe Research

MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn

2026-03-19T08:50:28.000Z - 5 months ago

MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn

MoonLake price target raised to $70 from $45 at Clear Street

2026-03-11T10:36:37.000Z - 5 months ago

MoonLake price target raised to $70 from $45 at Clear Street

MoonLake Immunotherapeutics Transcript: Investor Day 2026

Feb 23, 2026, 8:00 AM EST - 6 months ago

MoonLake Immunotherapeutics Transcript: Investor Day 2026

MoonLake Immunotherapeutics Slides: FY 2026

Feb 23, 2026, 8:00 AM EST - 6 months ago

MoonLake Immunotherapeutics Slides: FY 2026

MoonLake Immunotherapeutics Annual report: Q4 2025

Feb 22, 2026, 4:00 PM EST - 6 months ago

MoonLake Immunotherapeutics Annual report: Q4 2025

MoonLake Immunotherapeutics Earnings release: Q4 2025

Feb 22, 2026, 4:00 PM EST - 6 months ago

MoonLake Immunotherapeutics Earnings release: Q4 2025

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Feb 10, 2026, 7:00 AM EST - 6 months ago

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

IMA

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Feb 2, 2026, 8:00 AM EST - 7 months ago

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Jan 27, 2026, 7:30 AM EST - 7 months ago

Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering

Jan 23, 2026, 7:30 AM EST - 7 months ago

Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering

DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025

Dec 11, 2025, 8:54 AM EST - 8 months ago

DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025

MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money

Dec 5, 2025, 8:18 AM EST - 9 months ago

MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Dec 3, 2025, 7:46 AM EST - 9 months ago

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

Dec 1, 2025, 3:18 PM EST - 9 months ago

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

Nov 30, 2025, 7:45 AM EST - 9 months ago

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

Nov 24, 2025, 6:08 AM EST - 9 months ago

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

Nov 14, 2025, 6:08 AM EST - 9 months ago

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

Nov 10, 2025, 8:15 AM EST - 10 months ago

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

Nov 10, 2025, 6:06 AM EST - 10 months ago

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

MoonLake Immunotherapeutics Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 10 months ago

MoonLake Immunotherapeutics Earnings release: Q3 2025

MoonLake Immunotherapeutics Quarterly report: Q3 2025

Nov 5, 2025, 4:00 PM EST - 10 months ago

MoonLake Immunotherapeutics Quarterly report: Q3 2025

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Nov 5, 2025, 7:11 AM EST - 10 months ago

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Nov 5, 2025, 7:00 AM EST - 10 months ago

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

Nov 1, 2025, 7:08 AM EDT - 10 months ago

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

cranberry1
cranberry1 Aug. 19 at 7:54 PM
$MLTX 64
0 · Reply
badprecog
badprecog Aug. 19 at 7:45 PM
$MLTX Today is a very strong bio day, however I think once it is done going down, it will get back to $20 pretty quickly. At least that was my theory when I was trying to catch a falling knife yesteday.
1 · Reply
Mlbfan44
Mlbfan44 Aug. 19 at 7:44 PM
$MLTX
0 · Reply
pizzza
pizzza Aug. 19 at 7:28 PM
$MLTX
0 · Reply
Jkm11
Jkm11 Aug. 19 at 6:05 PM
$MLTX maybe someone knows something about something? Lol. Just some dumb humor to pass the time.
4 · Reply
Jkm11
Jkm11 Aug. 19 at 5:46 PM
$MLTX any explanation fot the out of the blue green candle? Weird after none in last week.
2 · Reply
perplex
perplex Aug. 19 at 5:08 PM
$MLTX That was quite a big volume candle for this time in the day..
2 · Reply
Horseblushew
Horseblushew Aug. 19 at 4:52 PM
$MLTX well now that you know i was 100% correct when i said this was a dead stock, do me a favor and tell that fucking scumbag pumper greasy, to go screw himself. this will be under $10 before you know it. BTW, did they get that break through drug designation greasy guaranteed??🤣🤣😂😂
0 · Reply
Antocar
Antocar Aug. 19 at 4:30 PM
$MLTX There remains uncertainty about SLK's efficacy in PsA. It is effective but has not yet proven to be a BIC. Therefore, the market is currently focusing on HS. Advanced results on PsA will be available in 2027, and then we'll see. At the moment, however, the euphoria surrounding SLK has greatly diminished.
0 · Reply
aletz
aletz Aug. 19 at 4:02 PM
$MLTX disappointing day, most bios are green and MLTX is not really budging, there's really very little excitement left and the management is doing a very poor job in marketing and promoting the science. They have hundreds of millions of dollars but has the most lame and boring linkedin posts.
1 · Reply
StockQB
StockQB Aug. 19 at 3:43 PM
$MLTX was supposed to move like todays $MRNA :/
1 · Reply
badprecog
badprecog Aug. 19 at 3:26 PM
$MLTX Some one poke it... Moonlake wake up!!! ;)
2 · Reply
WallStWolf38
WallStWolf38 Aug. 19 at 2:26 PM
$MLTX Trying to support a little bit 😅
0 · Reply
Inzamix89
Inzamix89 Aug. 19 at 2:23 PM
$MLTX if I am understanding correctly today’s news, it seems Moderna’s parterened program with Merck for melanoma is a success, removing the upcoming 2028 Keytruda patent phase out and replenishing the pipeline with new revenue income. It would mean there is no such big pressure on Merck to buy out Mltx or others, or?
4 · Reply
Jkm11
Jkm11 Aug. 19 at 1:42 PM
$MLTX i just exercised my 16call 7 contracts for friday. Figured its better than losing the 3k premium i paid for it 4 months ago. Now im left with jan 17 and jan 28 calls at 15 to 20 strikes, 180 2027 and 220 28 call options.
1 · Reply
Modern_portholio_theory
Modern_portholio_theory Aug. 19 at 1:33 PM
$MLTX wow shares avaiLble to borrow to short sky rocketed to 6 million theyve been busy buying back past couple days
2 · Reply
MichaelReiste
MichaelReiste Aug. 19 at 1:30 PM
$MLTX I'm ready
0 · Reply
Obidagreat
Obidagreat Aug. 19 at 1:18 PM
$MLTX
0 · Reply
Antocar
Antocar Aug. 19 at 12:45 PM
$MLTX Value could stabilize at $14-15. If BLA does well, maybe $25; if it does poorly, maybe $5. Place your bets.
1 · Reply
Antocar
Antocar Aug. 19 at 12:32 PM
$MLTX 15$ EOM
0 · Reply
Cardwizard
Cardwizard Aug. 19 at 11:52 AM
$MLTX today belongs to Moderna ,, congratulations longs
1 · Reply
SecoTrader
SecoTrader Aug. 19 at 9:07 AM
$MLTX my prediction is we are on sale and price is being discussed as we speak. I expect a BO around $48 before BLA submission. Not amazing, but for people who invested last October is good enough (including myself).
7 · Reply